+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic value of T1-mapping in TAVR patients: extra-cellular volume as a possible predictor for peri- and post-TAVR adverse events



Prognostic value of T1-mapping in TAVR patients: extra-cellular volume as a possible predictor for peri- and post-TAVR adverse events



International Journal of Cardiovascular Imaging 32(11): 1625-1633



The benefit of a transcatheter aortic valve replacement (TAVR) can differ in patients, and therapy bears severe risks. High-degree aortic stenosis can lead to cardiac damage such as diffuse myocardial fibrosis, evaluable by extra-cellular volume (ECV) in CMR. Therefore, fibrosis might be a possible risk factor for unfavorable outcome after TAVR. We sought to assess the prognostic value of T1-mapping and ECV to predict adverse events during and after TAVR. The study population consisted of patients undergoing clinically indicated TAVR by performing additional CMR with native and contrast-enhanced T1-mapping sequences for additional evaluation of ECV. Study endpoints were congestive heart failure (CHF) and TAVR-associated conduction abnormalities defined as new onset of left bundle branch block (LBBB), AV-Block or implantation of a pacemaker. 94 patients were examined and followed. Median follow up time was 187 days (IQR 79-357 days). ECV was increased (>30 %) in 38 patients (40 %). There was no significant correlation between ECV and death, Hazard ratio (HR) 0.847 (95 % CI 0.335; 2.14), p = 0.72. ECV in patients with subsequent CHF was higher than in those without an event (33.5 ± 4.6 and 29.1 ± 4.1 %, respectively), but the difference just did not reach the level of significance HR 2.16 (95 % CI 0.969; 4.84), p = 0.06. Patients with post-TAVR conduction abnormality (LBBB, AV-block or pacemaker implantation) had statistically relevant lower ECV values compared to those without an event. Patients with an event had a mean ECV of 28.1 ± 3.16 %; patients without an event had a mean ECV of 29.8 ± 4.53, HR 0.56 (95 % CI 0.32; 0.96), p = 0.036. In this study, elevated myocardial ECV is a predictor of CHF by trend; CMR may be helpful in identifying patients with a high risk for post-TAVR cardiac decompensation benefitting from an intensified post-interventional surveillance. Patients with post-TAVR conductions abnormalities have a significantly decreased ECV. Nevertheless, it remains unclear which precise molecular tissue alteration is the protective factor or risk factor in this case.

(PDF emailed within 0-6 h: $19.90)

Accession: 058637577

Download citation: RISBibTeXText

PMID: 27460767

DOI: 10.1007/s10554-016-0948-3


Related references

Challenges in Aortic Stenosis: Review of Antiplatelet/Anticoagulant Therapy Management with Transcatheter Aortic Valve Replacement (TAVR): TAVR with Recent PCI, TAVR in the Patient with Atrial Fibrillation, and TAVR Thrombosis Management. Current Cardiology Reports 20(12): 130, 2018

TCT-676 Prevalence of Residual Mitral and Tricuspid Regurgitation (MR/TR) following Transcatheter Aortic Valve Replacement (TAVR): Residual Mod/Severe MR and TR is Associated with Higher Mortality post TAVR. Journal of the American College of Cardiology 68(18): B273-B274, 2016

Serious adverse events in clinical trials with TAVR and SAVR. Herz 2018, 2018

Changing the Conversation to TAVR First!: Aftermath of the Low-Surgical Risk TAVR Studies. Jacc. Cardiovascular Interventions 12(10): 908-910, 2019

SCAI 2018 Think Tank "What should the role of the surgeon be in TAVR, both as a co-operator and in-patient evaluation for TAVR?. Catheterization and Cardiovascular Interventions 2018, 2018

Critical adverse events during transfemoral TAVR in conscious sedation. Is an anesthesiologic support mandatory?. Cardiovascular Revascularization Medicine 19(6s): 41-46, 2018

TAVR Prognosis, Aging, and the Second TAVR Tsunami: Insights From France. Journal of the American College of Cardiology 68(15): 1648-1650, 2018

Computer simulated "Virtual TAVR" to guide TAVR in the presence of a previous Starr-Edwards mitral prosthesis. Journal of Cardiovascular Computed Tomography 2018, 2018

Impact of Local Anesthesia Only Versus Procedural Sedation Using the Vancouver Clinical Pathway for TAVR: Insights From the 3M TAVR Study. Jacc. Cardiovascular Interventions 12(10): 1000-1001, 2019

Transthoracic echocardiogram-guided agitated-saline aortography for post-TAVR peri-prosthetic leak evaluation. European Heart Journal 36(21): 1305, 2016

Prognostic Value of Thoracic Aorta Calcification Burden in Patients Treated With TAVR. Jacc. Cardiovascular Imaging 2018, 2018

TCT-794 Derivation of TAVR Combined Mortality and Morbidity Risk Score for Predicting 1 year Mortality and Morbidity After TAVR. Journal of the American College of Cardiology 70(18): B270-B271, 2017

TCT-265 Impact of Peri-procedural Complications on Mortality and Quality of Life after TAVR. Journal of the American College of Cardiology 70(18): B109-B110, 2017

The safety of introducing a new generation TAVR device: one departments experience from introducing a second generation repositionable TAVR. Bmc Cardiovascular Disorders 17(1): 25, 2017

Prognostic Impact of Low-Flow Severe Aortic Stenosis in Small-Body Patients Undergoing TAVR: The OCEAN-TAVI Registry. Jacc. Cardiovascular Imaging 11(5): 659-669, 2017